What FDA has decided so far
BPC-157 legal status for your pharmacy question
FDA lists BPC-157 under withdrawn nominations and still notes safety concerns. A provider’s prescription does not mean FDA approved the drug.
Why was BPC-157 on FDA’s July 2026 agenda?
FDA held a public meeting on July 23-24, 2026 with BPC-157 on the agenda. An outside group was set to discuss whether pharmacies may start with raw BPC-157 to make a medicine [18]. The agenda also named TB-500, another lab-made string of protein parts. Before the meeting, FDA staff advised against adding BPC-157 to the list pharmacies may use.
A meeting isn’t a ruling. The outside group’s job is to study the facts and advise FDA [18]. FDA makes the final choice and doesn’t have to follow that advice [17]. That meeting did not grant FDA approval.
The cited agenda records the discussion topic, not a vote or final listing decision [18]. You may keep watching FDA’s pages if the pharmacy question matters to you. You can’t treat the meeting as permission.
What has FDA decided so far?
FDA formerly placed two forms of BPC-157 in Category 2, the group for raw ingredients tied to serious safety concerns. The people seeking permission withdrew both BPC-157 nominations [16]. FDA now lists those nominations as withdrawn, outside Category 2 [16]. Pulling the requests didn’t erase the safety concern.
FDA named two worries. With some ways of giving BPC-157, a person’s immune system might react. It is a peptide, meaning a short string of protein parts. FDA also warned that a peptide product may not contain exactly what its label says [16].
The part that matters is plain. A pulled request ends the request, but it isn’t approval or a final ban [16][17]. Withdrawal does not establish whether a pharmacy may fill an individual request. Prescription access now exists, with a licensed provider and pharmacy responsible for their own decisions.
BPC-157 also lacks approval as a finished drug. Drug approval and permission to start with a raw ingredient are separate choices. BPC-157’s withdrawn nominations do not establish either approval [17][16]. I’d want that difference clear before calling a pharmacy.
When may a pharmacy start with a raw ingredient?
U.S. law treats two kinds of drug making differently. A state-licensed pharmacy may prepare a drug for a named patient. An FDA-registered drug maker may make larger batches for medical offices [17]. Each kind follows different rules that affect your order.
A raw ingredient has only one of three paths. It may already appear in an FDA-approved medicine, have a recognized recipe and quality rule, or be on an FDA list that tells pharmacies which ingredients are allowed [17]. If none fits, a request can go to FDA for review. An outside group may then study that request.
FDA’s interim policy distinguishes Category 1 from Category 2 [17][19]. For the first group, FDA may choose not to take action when the policy’s conditions are met [17]. Category 2 reflects significant safety concerns and is outside that policy’s protection [17]. BPC-157 is now listed among withdrawn nominations, rather than in either numbered group [16].
Changing or pulling an old Category 2 request didn’t give a pharmacy short-term permission. Both BPC-157 nominations are withdrawn. FDA’s entry for the withdrawn nominations still describes safety concerns [16]. That entry does not grant a pharmacy permission to compound BPC-157.
What can you ask your doctor and pharmacy?
A licensed doctor first decides whether a pharmacy-made medicine fits one named patient [17]. Your visit may be in person or by telehealth, which means a lawful phone or video visit. If the drug is lawful and fits your case, the doctor writes an order. Your state-licensed pharmacy then decides whether to fill it [17].
A video visit can’t change which raw ingredients your pharmacy may use [17]. A valid visit and order are still required. BPC-157 requests at Promise Peptides (mypromise.com) are checked by a U.S.-licensed clinician before prescribing. The provider reviews each request and may decline it; care is for U.S. patients, and options depend on the state and the treatment.
If I called, I’d ask the pharmacy to state the current rule plainly. This page explains access without taking orders or setting a dose. The focus is U.S. prescribing and pharmacy rules. Your doctor and pharmacist must decide what is lawful for you.
Is BPC-157 approved, allowed, or banned?
There isn’t one yes-or-no answer for every setting. The substance doesn’t have FDA drug approval. FDA formerly placed the raw ingredient in Category 2, its safety-warning group; the nominations are now withdrawn [16]. That step concerned pharmacies, not every law that may apply to you.
Sports rules are clearer. Under World Anti-Doping Agency rules, athletes can’t use BPC-157 at any time. Your legal answer depends on where you live and why it might be used. This page covers U.S. pharmacy rules; you may still need local legal advice.
Can a pharmacy make BPC-157 right now?
BPC-157 is available by prescription after a licensed U.S. provider’s review. FDA formerly listed BPC-157 in Category 2 for serious safety concerns. The nominations are now withdrawn [16]. Withdrawal does not grant FDA approval for compounding.
A doctor’s review can’t settle what a pharmacy may legally make. A request may be declined, and access depends on the state and the treatment. An outside FDA group had BPC-157 on its July 2026 agenda [18]. The meeting did not approve BPC-157; compounded medicines have no FDA approval.
Why did FDA change its BPC-157 listing?
FDA formerly listed BPC-157 in Category 2, its safety-warning group. The filers withdrew both BPC-157 nominations, which now appear in FDA’s withdrawn list [16]. Withdrawal did not authorize a pharmacy to make BPC-157. The two requests covered two lab forms of the same substance [16].
FDA also put BPC-157 on a July 23-24, 2026 meeting agenda. An outside group was to talk over whether pharmacies may make medicine from the raw ingredient [18]. A place on the agenda isn’t permission or a final choice. Prescription review is available now; FDA drug approval remains separate.